Powered by: Motilal Oswal

News

Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services Strides Pharma Science is currently trading at Rs. 479.80, up by 21.15 points or 4.61% from its previous closing of Rs. 458.65 on the BSE. The scrip opened at Rs. 458.00 and has touched a high and low of Rs. 485.50 and Rs. 458.00 respectively. So far 32126 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.85 on 01-Aug-2023 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip...
Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services
Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services
Source: Accord Fintech
7/09/2023 12:05:52 PM
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension Strides Pharma Science is currently trading at Rs. 437.95, up by 2.00 points or 0.46% from its previous closing of Rs. 435.95 on the BSE. The scrip opened at Rs. 435.10 and has touched a high and low of Rs. 445.75 and Rs. 435.10 respectively. So far 6078 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.85 on 01-Aug-2023 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip s...
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension
Source: Accord Fintech
30/08/2023 12:47:16 PM
Strides Pharma Science shines on getting EIR from USFDA for Puducherry manufacturing facility Strides Pharma Science is currently trading at Rs. 366.50, up by 7.10 points or 1.98% from its previous closing of Rs. 359.40 on the BSE. The scrip opened at Rs. 364.85 and has touched a high and low of Rs. 375.00 and Rs. 363.30 respectively. So far 5955 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 392.20 on 22-Dec-2022 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip s...
Strides Pharma Science shines on getting EIR from USFDA for Puducherry manufacturing facility
Strides Pharma Science shines on getting EIR from USFDA for Puducherry manufacturing facility
Source: Accord Fintech
19/05/2023 9:48:32 AM
Strides Pharma Science surges on entering into strategic partnership with Orbicular Strides Pharma Science is currently trading at Rs. 339.20, up by 3.65 points or 1.09% from its previous closing of Rs. 335.55 on the BSE. The scrip opened at Rs. 337.00 and has touched a high and low of Rs. 340.70 and Rs. 330.35 respectively. So far 19785 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 392.20 on 22-Dec-2022 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip ...
Strides Pharma Science surges on entering into strategic partnership with Orbicular
Strides Pharma Science surges on entering into strategic partnership with Orbicular
Source: Accord Fintech
3/05/2023 12:30:47 PM
Buy Strides Pharma Science Ltd For Target Rs.462 - ICICI Securities Regulated markets drive growth Strides Pharma Science’s (Strides) Q3FY23 performance fell short of our revenue expectations, mainly due to negligible sales in the institutional business. Revenues grew 8.9% YoY (-3.6% QoQ) to Rs.8.7bn (I-Sec: Rs10bn). US sales were up 5% QoQ to US$63mn (I-Sec: US$60mn) driven by volume growth and traction in new product launches. Emerging market revenues fell 73.9% QoQ to US$6mn. Institutional business saw negligible revenues during the quarter due to...
Buy Strides Pharma Science Ltd For Target Rs.462 - ICICI Securities
Buy Strides Pharma Science Ltd For Target Rs.462 - ICICI Securities
Source: ICICI Securities Ltd
26/01/2023 11:57:26 AM
Buy Strides Pharma Science Ltd For Target Rs 345 - ICICI Securities Strides Pharma Science Strong recovery in US sales Strides Pharma Science’s (Strides) Q2FY23 performance fell short of our estimates due to underperformance in regulated markets other than the US, which reported strong recovery with a 30% QoQ rise to US$60mn. Revenues grew 24.3% YoY to Rs9.0bn (I-Sec: Rs9.4bn) led by the strong US growth. Institutional business remained soft with closure of contracts (renewals are to begin in FY24). Higher US sales drove operating leverage, suppor...
Buy Strides Pharma Science Ltd For Target Rs 345 - ICICI Securities
Buy Strides Pharma Science Ltd For Target Rs 345 - ICICI Securities
Source: ICICI Securities
10/01/2023 1:04:53 PM
Strides Pharma Science trades higher on the BSE Strides Pharma Science is currently trading at Rs. 370.20, up by 5.95 points or 1.63% from its previous closing of Rs. 364.25 on the BSE. The scrip opened at Rs. 369.00 and has touched a high and low of Rs. 373.25 and Rs. 364.05 respectively. So far 4790 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 466.60 on 18-Jan-2022 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip s...
Strides Pharma Science trades higher on the BSE
Strides Pharma Science trades higher on the BSE
Source: Accord Fintech
23/12/2022 10:08:09 AM
Strides Pharma Science soars as its arm gets AUD 94 million as deferred consideration for sale of Australian operations Strides Pharma Science is currently trading at Rs. 375.80, up by 9.70 points or 2.65% from its previous closing of Rs. 366.10 on the BSE. The scrip opened at Rs. 368.10 and has touched a high and low of Rs. 392.20 and Rs. 368.10 respectively. So far 78020 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 466.60 on 18-Jan-2022 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip ...
Strides Pharma Science soars as its arm gets AUD 94 million as deferred consideration for sale of Australian operations
Strides Pharma Science soars as its arm gets AUD 94 million as deferred consideration for sale of Australian operations
Source: Accord Fintech
22/12/2022 11:58:35 AM
Buy Strides Pharma Ltd For Target Rs.380 - Motilal Oswal Financial Services ANDA launches and other regulated markets to sustain better prospects ? STR delivered an in line revenue in 1QFY23. However, there has been an uptick in the margin on a sequential basis. The spillover of revenue for the US market to 2QFY23 and currency headwinds in other regulated markets (OTR) resulted in a lower than expected EBITDA margin in 1QFY23. ? We value STR on a SoTP basis, with an EV/EBITDA of 9x for its regulated and emerging markets, 6x for its Institutional segment, and ad...
Buy Strides Pharma Ltd For Target Rs.380 - Motilal Oswal Financial Services
Buy Strides Pharma Ltd For Target Rs.380 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
14/09/2022 10:45:45 AM
Strides Pharma rises as its arm receives EIR from USFDA for Drug Products facility in Bengaluru Strides Pharma Science is currently trading at Rs. 336.00, up by 5.10 points or 1.54 % from its previous closing of Rs. 330.90 on the BSE. The scrip opened at Rs. 330.10 and has touched a high and low of Rs. 336.00 and Rs. 330.10 respectively. So far 2513 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 642.10 on 15-Sep-2021 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip ...
Strides Pharma rises as its arm receives EIR from USFDA for Drug Products facility in Bengaluru
Strides Pharma rises as its arm receives EIR from USFDA for Drug Products facility in Bengaluru
Source: Accord Fintech
1/09/2022 10:13:15 AM
Value of promoter holding in BSE-500 stocks decline to 1.5% in June quarter: Kotak report The value of promoter pledge holding as a percentage of promoter holding declined to 1.5 per cent in the April-June quarter from 1.7 per cent in the previous quarter, according to the Kotak Institutional Equities report. Promoters of 81 companies in the BSE-500 Index have pledged part of their holdings in the June 2022 quarter. Only three companies had more than 80 per cent of their promoter holdings pledged. These companies are Thyrocare Technologies, Max Financial Services and Suzlon ...
Value of promoter holding in BSE-500 stocks decline to 1.5% in June quarter: Kotak report
Value of promoter holding in BSE-500 stocks decline to 1.5% in June quarter: Kotak report
Source: IANS
21/08/2022 9:32:23 AM
Strides Pharma soars as its arm gets USFDA`s approval for Cyclosporine Softgel Capsules Strides Pharma Science is currently trading at Rs. 348.15, up by 13.35 points or 3.99% from its previous closing of Rs. 334.80 on the BSE. The scrip opened at Rs. 335.55 and has touched a high and low of Rs. 350.95 and Rs. 335.00 respectively. So far 29383 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 809.00 on 03-Aug-2021 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip...
Strides Pharma soars as its arm gets USFDA`s approval for Cyclosporine Softgel Capsules
Strides Pharma soars as its arm gets USFDA`s approval for Cyclosporine Softgel Capsules
Source: Accord Fintech
3/08/2022 3:09:07 PM
Strides Pharma Scien posts Q1 net loss of Rs 66.25 cr The company reported standalone net loss during the quarter stood at Rs 66.25 crore as compared to net loss of Rs 21.23 crore in the previous year quarter. Net revenue of the company declined moderately by 16.82 per cent at Rs 423.19 crore in April-June quarter of this fiscal as against Rs 508.79 crore in the corresponding period last year. During April-June quarter, operating expenses dropped by 3.27 per cent to Rs 484.22 crore from Rs 500.60 crore in year ago period. Other Income dipped ...
Strides Pharma Scien posts Q1 net loss of Rs 66.25 cr
Strides Pharma Scien posts Q1 net loss of Rs 66.25 cr
Source: Dion Global Solutions Ltd
29/07/2022 2:41:24 PM
Strides Pharma Science gets nod to raise Rs 150 crore via NCDs Strides Pharma Science’s board has approved the offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, non-convertible debentures (NCDs) of face value Rs 10 lakh each, aggregating up to Rs 150 crore. The board of directors, at its meeting, held on July 25, 2022 has considered and approved the same. Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture o...
Strides Pharma Science gets nod to raise Rs 150 crore via NCDs
Strides Pharma Science gets nod to raise Rs 150 crore via NCDs
Source: Accord Fintech
26/07/2022 9:24:26 AM
Small Cap : Strides Pharma Science Ltd For Target Rs.355 - Geojit Financial Services Healthy sequential growth across geographies Strides Pharma Science (STAR) is an R&D focussed, vertically integrated pharmaceutical company with an experienced management team having presence across multiple therapeutic segments. • Strides reported its Q4FY22 revenue at Rs.866cr (9% QoQ, -4.7% YoY), with the US business (38% of total revenue) clocking 17% QoQ growth. • Unusual price erosion and volume drops in the US led to contraction in EBITDA (-73.4% YoY) to Rs.42cr ...
Small Cap : Strides Pharma Science Ltd For Target Rs.355 - Geojit Financial Services
Small Cap : Strides Pharma Science Ltd For Target Rs.355 - Geojit Financial Services
Source: Geojit Financial Services Ltd
24/06/2022 12:45:51 PM
Strides Pharma Science declines after its arm recalls over six lakh bottles of Losartan Potassium tablets in US Strides Pharma Science is currently trading at Rs. 301.85, down by 12.35 points or 3.93% from its previous closing of Rs. 314.20 on the BSE. The scrip opened at Rs. 306.70 and has touched a high and low of Rs. 308.90 and Rs. 298.10 respectively. So far 17472 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 847.45 on 11-Jun-2021 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scr...
Strides Pharma Science declines after its arm recalls over six lakh bottles of Losartan Potassium tablets in US
Strides Pharma Science declines after its arm recalls over six lakh bottles of Losartan Potassium tablets in US
Source: Accord Fintech
13/06/2022 12:06:28 PM
Strides Pharma Science shines as its arm gets USFDA’s nod for Ibuprofen Oral Suspension Strides Pharma Science is currently trading at Rs. 331.75, up by 5.15 points or 1.58% from its previous closing of Rs. 326.60 on the BSE. The scrip opened at Rs. 332.45 and has touched a high and low of Rs. 334.50 and Rs. 329.80 respectively. So far 4512 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 847.45 on 11-Jun-2021 and a 52 week low of Rs. 263.45 on 11-May-2022. Last one week high and low of the scrip s...
Strides Pharma Science shines as its arm gets USFDA’s nod for Ibuprofen Oral Suspension
Strides Pharma Science shines as its arm gets USFDA’s nod for Ibuprofen Oral Suspension
Source: Accord Fintech
30/05/2022 9:58:13 AM
Strides Pharma Science Q4 net profit zooms 317.01% at Rs 200.50 cr The company reported standalone net profit of Rs 200.50 crore for the quarter ended March 31, 2022 as compared to Rs 48.08 crore in the same period last year, registering a year-on-year growth of 317.01 per cent. Net revenue of the company declined substantially by 28.08 per cent at Rs 455.66 crore in January-March quarter of this fiscal as against Rs 633.60 crore in the corresponding period last year. During January-March quarter, operating expenses dropped by 19.75 per cent to Rs 437.82 cro...
Strides Pharma Science Q4 net profit zooms 317.01% at Rs 200.50 cr
Strides Pharma Science Q4 net profit zooms 317.01% at Rs 200.50 cr
Source: Dion Global Solutions Ltd
25/05/2022 2:03:54 PM
Strides Pharma Science surges on inking sub-license agreement with MPP Strides Pharma Science is currently trading at Rs. 347.50, up by 13.40 points or 4.01% from its previous closing of Rs. 334.10 on the BSE. The scrip opened at Rs. 336.65 and has touched a high and low of Rs. 349.25 and Rs. 336.05 respectively. So far 37472 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 946.80 on 23-Apr-2021 and a 52 week low of Rs. 304.50 on 04-Mar-2022. Last one week high and low of the scrip...
Strides Pharma Science surges on inking sub-license agreement with MPP
Strides Pharma Science surges on inking sub-license agreement with MPP
Source: Accord Fintech
21/03/2022 11:22:00 AM
Strides Pharma Science inches up as its arm gets USFDA approval for Colchicine Tablets Strides Pharma Science is currently trading at Rs. 331.30, up by 1.80 points or 0.55% from its previous closing of Rs. 329.50 on the BSE. The scrip opened at Rs. 330.00 and has touched a high and low of Rs. 333.60 and Rs. 323.05 respectively. So far 74196 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 946.80 on 23-Apr-2021 and a 52 week low of Rs. 304.50 on 04-Mar-2022. Last one week high and low of the scrip ...
Strides Pharma Science inches up as its arm gets USFDA approval for Colchicine Tablets
Strides Pharma Science inches up as its arm gets USFDA approval for Colchicine Tablets
Source: Accord Fintech
11/03/2022 1:09:44 PM
Buy Strides Pharma Ltd For Target Rs.450 - Motilal Oswal EBTDA breakeven in 3QFY22 Work in progress to enhance its sales prospects across key markets * STR delivered in line revenue in 3QFY22. Compared to operational loss in the previous two quarters, it saw a break even at the EBITDA level in 3QFY22. The escalated raw material cost kept EBITDA under check. * With traction in the drug product business, Stelis has achieved an EBITDA breakeven in 3QFY22. Customer addition is providing business opportunities starting from FY23. * We have c...
Buy Strides Pharma Ltd For Target Rs.450 - Motilal Oswal
Buy Strides Pharma Ltd For Target Rs.450 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
11/02/2022 10:27:25 AM
Stock Picks - Power Grid Corporation of India Ltd And Strides Pharma Science Ltd​​​​​​​​​​​​​​​​​​​​​ By ICICI Direct Power Grid Corporation of India Buy Power Grid Corporation of India Ltd @ 209.00-210.00 CMP 213.50 TGT 213.50 SL 207.40   Strides Pharma Science Ltd Buy Strides Pharma Science  Ltd @ 390.00-392.00 CMP 389.75 TGT 384.00 SL 394.70   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by...
Stock Picks - Power Grid Corporation of India Ltd And Strides Pharma Science Ltd​​​​​​​​​​​​​​​​​​​​​ By ICICI Direct
Stock Picks - Power Grid Corporation of India Ltd And Strides Pharma Science Ltd​​​​​​​​​​​​​​​​​​​​​ By ICICI Direct
Source: ICICI Direct
9/02/2022 10:28:55 AM
Buy Strides Pharma Ltd For Target Rs.580 - Motilal Oswal US segment drags overall performance Recovery witnessed in non-US markets * STR reported a lower than expected performance in 2QFY22 due to continued headwinds in the US business. Sales in other regulated markets witnessed a recovery, with an 18% YoY growth. * With the completion of Endo products and facility acquisition, STR will have a diversified US portfolio, with a lower proportion of Acute products as well as differentiated products such as hormones, Nasal Sprays, Gels, Modifi...
Buy Strides Pharma Ltd For Target Rs.580 - Motilal Oswal
Buy Strides Pharma Ltd For Target Rs.580 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
1/01/2022 11:33:29 AM
Strides Pharma Science surges as its Stelis commissions greenfield vaccine manufacturing facility at Bengaluru Strides Pharma Science is currently trading at Rs. 423.00, up by 11.10 points or 2.69% from its previous closing of Rs. 411.90 on the BSE. The scrip opened at Rs. 426.50 and has touched a high and low of Rs. 426.50 and Rs. 420.50 respectively. So far 5923 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1000.00 on 08-Jan-2021 and a 52 week low of Rs. 403.55 on 20-Dec-2021. Last one week high and low of the scrip...
Strides Pharma Science surges as its Stelis commissions greenfield vaccine manufacturing facility at Bengaluru
Strides Pharma Science surges as its Stelis commissions greenfield vaccine manufacturing facility at Bengaluru
Source: Accord Fintech
21/12/2021 10:55:49 AM
Hold Strides Pharma Science Ltd For Target Rs.500 - ICICI Securities Disappointing Q2; outlook weakens Strides Pharma Science (Strides) reported another quarter of disappointing performance in Q2FY22 with US sales declining 17.1% QoQ (-37.0% YoY) to US$34mn. Despite other segments reporting growth, high raw material and operational costs coupled with lower revenue have severely impacted EBITDA and margins. Company has delayed its US sales guidance of US$220-230mn by several quarters highlighting weakness in the business. Revenue declined 9.1% YoY to Rs7.2bn...
Hold Strides Pharma Science Ltd For Target Rs.500 - ICICI Securities
Hold Strides Pharma Science Ltd For Target Rs.500 - ICICI Securities
Source: ICICI Securities Ltd
16/12/2021 12:21:30 PM
Stock Picks - Oil and Natural Gas Corporation Ltd and Strides Pharma Science Ltd By ICICI Direct Oil and Natural Gas Corporation Buy Oil and Natural Gas Corporation Ltd @ 161.00-161.50 CMP 161.45 TGT 164.20 SL 159.60   Strides Pharma Science Ltd Sell Strides Pharma Science Ltd @ 535.00-537.00 CMP 533.25 TGT 530.60 SL 541.40   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views ...
Stock Picks - Oil and Natural Gas Corporation Ltd and Strides Pharma Science Ltd By ICICI Direct
Stock Picks - Oil and Natural Gas Corporation Ltd and Strides Pharma Science Ltd By ICICI Direct
Source: ICICI Direct
26/10/2021 10:48:16 AM
Stock Picks - Canara Bank Ltd and Strides Pharma Science Ltd By ICICI Direct Canara Bank Buy Canara Bank Ltd @ 195.00-196.00 CMP 195.90 TGT 199.20 SL 193.40   Strides Pharma Sell Strides Pharma Science Ltd @ 545.00-547.00 CMP 545.00 TGT 540.60 SL 551.60   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all participants are for information &...
Stock Picks - Canara Bank Ltd and Strides Pharma Science Ltd By ICICI Direct
Stock Picks - Canara Bank Ltd and Strides Pharma Science Ltd By ICICI Direct
Source: ICICI Direct
21/10/2021 11:51:50 AM
Hold Strides Pharma Science Ltd For Target Rs.720 - ICICI Securities Weak Q1; operating deleverage hits harder Strides Pharma Science (Strides) reported disappointing performance in Q1FY22 with lower revenue across businesses impacting margins. Revenue declined 12.0% YoY to Rs6.9bn (I-Sec: Rs9.1bn) due to fall in US and other regulated markets. This was primarily on account of covid related disruptions affecting demand and supplies and double digit price erosion. This also led to operating deleverage as expenses were at normal levels which along with dro...
Hold Strides Pharma Science Ltd For Target Rs.720 - ICICI Securities
Hold Strides Pharma Science Ltd For Target Rs.720 - ICICI Securities
Source: ICICI Securities
29/09/2021 10:07:01 AM
Buy Strides Pharma Ltd For Target Rs.840 - Motilal Oswal Lack of launches / COVID disruption leads to weak 1QFY22 New launches – key for business revival * Strides Pharma (STR) reported unexpected operational loss in 1QFY22 on lower demand, higher competitive intensity in US Generics, and low operating leverage. This was exacerbated by the impact on production and supply due to a severe second COVID wave in Bengaluru.   * As a quick mitigation plan to increase product launches, it aims to acquire a portfolio of differentiated...
Buy Strides Pharma Ltd For Target Rs.840 - Motilal Oswal
Buy Strides Pharma Ltd For Target Rs.840 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
14/09/2021 11:55:47 AM
MTF Stock Pick Buy Strides Pharma Science Limited For Target Rs. 785 - HDFC Securities MTF Stock Pick Buy Strides Pharma Science Limited For Target Rs. 785 - HDFC Securities  TECHNICAL OBSERVATIONS The attached Daily timeframe chart of STAR, which was falling from last few sessions but in the last 2 sessions it has taken a support on its earlier bottom and bounced. The stock has also made double bottom formation on daily and weekly chart. The stock has also taken support trend line expecting bounce from current level. We observe a formati...
MTF Stock Pick Buy Strides Pharma Science Limited For Target Rs. 785 - HDFC Securities
MTF Stock Pick Buy Strides Pharma Science Limited For Target Rs. 785 - HDFC Securities
Source: HDFC Securities Ltd
13/08/2021 1:02:40 PM
Add Strides Pharma Science Ltd For Target Rs. 906 - ICICI Securities Strong growth; margin hit by higher costs Strides Pharma Science (Strides) reported a steady Q4FY21 performance with strong revenue growth, although margin was impacted by higher logistics costs. Revenue grew 46.9% YoY to Rs9.1bn (I-Sec: Rs8.5bn) with strong growth across businesses and EBITDA margin improved 400bps to 17.5% (I-Sec: 19.8%) but Q4FY20 was a low base due to ranitidine ban. Sequentially EBITDA margin dropped 170bps due to higher logistics costs despite strong revenue growth. ...
Add Strides Pharma Science Ltd For Target Rs. 906 - ICICI Securities
Add Strides Pharma Science Ltd For Target Rs. 906 - ICICI Securities
Source: ICICI Securities
28/06/2021 10:55:38 AM
Buy Strides Pharma Ltd For Target Rs.930 - Motilal Oswal US/Institutional business drives earnings Work-in-progress to build a basket of COVID-19 products * STR’s 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of COVID-19. In addition to commercial manufacturing of the Sputnik vaccine by Oct’21, STR is building a basket of COVID-related medicines. The ANDA filing moment...
Buy Strides Pharma Ltd For Target Rs.930 - Motilal Oswal
Buy Strides Pharma Ltd For Target Rs.930 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
21/06/2021 12:13:12 PM
Quote on Today`s Top Gainers Stocks by Mr. Sameet Chavan, Angel Broking Ltd Below are Quote on Today's Top Gainers Stocks by Mr. Sameet Chavan, Chief Analyst-Technical and Derivatives, Angel Broking Ltd  1. SUNPHARMA ADV. - Some of the midcap PHARMA stocks are buzzing today since morning. This stock has finally come out of its recent consolidation zone. We expect the move to extend towards 262 – 265 over the next few days. The support zone is visible around 235 – 230. 2. PIRAMAL ENT. - We have been upbeat on this stock since last ...
Quote on Today`s Top Gainers Stocks by Mr. Sameet Chavan, Angel Broking Ltd
Quote on Today`s Top Gainers Stocks by Mr. Sameet Chavan, Angel Broking Ltd
Source: Angel Broking Ltd
8/06/2021 3:03:59 PM
Small Cap : Buy Strides Pharma Science Ltd For Target Rs.936 - Geojit Financial Strong growth across geographies.. Strides Pharma Science (STAR) is an R&D focussed, vertically integrated pharmaceutical company with an experienced management team having presence across multiple therapeutic segments. * Strides revenues in Q4FY21 grew by 47% YoY to Rs.908 cr during the quarter with sales growth in the regulated markets and emerging markets. * The emerging markets grew by 107% YoY with growth in institutional biz. driven by TDL. * The company announced its pa...
Small Cap : Buy Strides Pharma Science Ltd For Target Rs.936 - Geojit Financial
Small Cap : Buy Strides Pharma Science Ltd For Target Rs.936 - Geojit Financial
Source: Geojit Financial Services Ltd
4/06/2021 11:32:42 AM
Strides Pharma Science gains on inking pact with TLC to launch Liposomal Amphotericin B Strides Pharma Science is currently trading at Rs. 817.30, up by 9.95 points or 1.23% from its previous closing of Rs. 807.35 on the BSE.   The scrip opened at Rs. 809.00 and has touched a high and low of Rs. 818.25 and Rs. 809.00 respectively. So far 2645 shares were traded on the counter.   The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1000.00 on 08-Jan-2021 and a 52 week low of Rs. 387.70 on 12-Jun-2020.   Last one w...
Strides Pharma Science gains on inking pact with TLC to launch Liposomal Amphotericin B
Strides Pharma Science gains on inking pact with TLC to launch Liposomal Amphotericin B
Source: Accord Fintech
28/05/2021 10:30:50 AM
LKP Spade, Weekly Pick - Buy Strides Pharma Science Limited For Target Rs.980 - LKP Securities * Stock has moved above its strong hurdle zone as seen on chart. * Strong volume activity has been witnessed at the time of breakout. * Both momentum indicator RSI & MACD are ranging in positive territory . Buy Strides Pharma Science Limited @900-907 TGT 980 Stop Loss Below Rs. 850 CB Duration 1 Week     To Read Complete Report & Disclaimer Click Here   For More  LKP Securities Ltd Disclaimer  http://ww...
LKP Spade, Weekly Pick - Buy Strides Pharma Science Limited For Target Rs.980 - LKP Securities
LKP Spade, Weekly Pick - Buy Strides Pharma Science Limited For Target Rs.980 - LKP Securities
Source: LKP Securities Ltd
19/04/2021 10:31:31 AM
Add Strides Pharma Science Ltd For Target Rs. 939 - ICICI Securities Steady quarter; Stelis to demerge Strides Pharma Science (Strides) reported a steady Q3FY21 performance, though reduction in export incentives and continued losses in JV/associates impacted net profit. Revenue grew 13.6% YoY to Rs8.3bn (I-Sec: Rs8.2bn) with strong growth in other regulated markets, EBITDA margin declined 550bps to 19.2% (ISec: 19.9%) and adjusted PAT declined 39.7% YoY to Rs475mn (I-Sec: Rs601mn). US declined 1.9% QoQ to US$53mn due to weak flu season. The Board has approv...
Add Strides Pharma Science Ltd For Target Rs. 939 - ICICI Securities
Add Strides Pharma Science Ltd For Target Rs. 939 - ICICI Securities
Source: ICICI Securities
23/02/2021 9:50:59 AM
Strides up by 2.5% on positive development of receiving approval from USFDA By Yash Gupta, Angel Broking Below are Views On Strides up by 2.5% on positive development of receiving approval from USFDA By Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd “Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equival...
Strides up by 2.5% on positive development of receiving approval from USFDA By Yash Gupta, Angel Broking
Strides up by 2.5% on positive development of receiving approval from USFDA By Yash Gupta, Angel Broking
Source: Angel Broking Ltd
12/02/2021 1:45:50 PM
Buy Strides Pharma Ltd For Target Rs.980 - Motilal Oswal Slower US/Africa biz drag down earnings Robust growth outlook for other regulated market business * Strides Pharma (STR)’s 3QFY21 performance came in below estimates due to the COVID-related impact on the US and Africa biz. Recovery in the Other Regulated (OTR) business was led by healthy volume traction. At the strategic level, STR would de-merge its Biotech business under Stelis Biopharma and intends to list this, thereby unlocking value for shareholders. * We cut our earning...
Buy Strides Pharma Ltd For Target Rs.980 - Motilal Oswal
Buy Strides Pharma Ltd For Target Rs.980 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
5/02/2021 10:41:54 AM